Cells are delivered through a single IV infusion.
Autoimmune disease is a failure of self-tolerance: the immune system attacks the body's own tissue. Mesenchymal stem cells are delivered into the bloodstream by IV infusion, where they promote regulatory T-cells and reduce the inflammatory cytokines that drive the disease. This therapy is used alongside the medication plan from your rheumatologist or treating specialist.
A standard protocol uses 50 million cells and a high-dose protocol uses 100 million. The infusion takes 60 to 90 minutes, and you leave the clinic the same day.
We treat six families of autoimmune conditions.
The conditions we treat in each family, and every IV protocol we run for it. The final prescription is always the physician's, after your records and disease-activity data are reviewed.
No match for that term. Try the condition’s medical name instead, or ask a physician directly — this list covers the most common indications, not every one.
Doses run from 50 to 100 million cells.
Every dose is expanded from Wharton's jelly umbilical-cord tissue, tested for viability, and scaled to the condition and the activity of disease.
50M
cells in the standard anti-inflammatory IV protocol — the systemic starting point for most autoimmune cases.
100M
cells in the high-dose IV protocol, for more active or refractory disease — always at the physician's discretion.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens in the bloodstream.
Tap a step to follow the cells from the IV line into circulation.
What the response looks like.
A typical systemic protocol timeline, measured against your own disease-activity baseline. Your physician tailors it to your condition and your case.
Day 0
Monitored IV infusion
60–90 minutes in a private suite. Most patients report nothing beyond mild transient fatigue or flushing in the first 24 hours. You continue all prescribed medications unless your own specialist directs otherwise.
Weeks 2–8
Early signals
Where there is a response, patients often notice it first as reduced stiffness, fatigue, or flare frequency. Early changes tend to be modest.
Months 3–6
Primary reassessment
Structured re-measurement of your disease-activity score and inflammatory markers, ideally shared with your treating specialist.
Beyond 6 months
Durability & medication review
Any tapering of immunosuppression is your prescribing specialist's decision, based on measured disease control. Chronic cases often benefit from a booster infusion at 9 to 12 months.
The evidence, briefly.
Three anchor findings from the peer-reviewed autoimmune literature.
RCT
Phase 3 randomized, placebo-controlled trial: allogeneic MSCs achieved significantly higher healing of Crohn's perianal fistulas — a therapy since approved in Europe.
Panés J, et al. The Lancet, 2016.
IV MSC
Randomized, placebo-controlled phase Ib/IIa trial of intravenous allogeneic MSCs in refractory rheumatoid arthritis reported acceptable safety and improved disease-activity signals.
Álvaro-Gracia JM, et al. Ann Rheum Dis, 2017.
Meta‑analysis
Updated systematic review of intravascular MSC administration: adverse events typically mild, transient, and self-limited; serious events rare.
Thompson M, et al. EClinicalMedicine, 2020.
The evidence base for MSC therapy in autoimmune disease is genuinely uneven, and it deserves to be read that way. For Crohn's perianal fistula it is randomized, controlled, and strong enough to have earned regulatory approval in Europe; for rheumatoid arthritis and lupus it is controlled but early, with larger confirmatory trials still needed; for multiple sclerosis and thyroid disease it is earlier still — promising safety data, not definitive efficacy. None of it guarantees a result for any individual. This therapy is an adjunct to specialist-led rheumatology, gastroenterology, endocrinology, or neurology care, not a replacement for it — stopping disease-modifying medication to pursue cell therapy is a reason we would advise against proceeding. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your diagnosis, disease-activity data, and current treatment.
